Eli Lilly Launches Mounjaro in India: A New Hope for Diabetes and Obesity
A Growing Health Crisis in India
In India, approximately 101 million individuals are affected by diabetes, with over half struggling to manage their blood sugar levels. Concurrently, around 100 million people are grappling with obesity. A new medication promises to address both issues effectively.
Eli Lilly, an American pharmaceutical firm, has introduced its diabetes and weight management medication, Mounjaro, in India following approval from the country's drug regulatory authority. The company announced this development on Thursday. The cost for a 5 MG vial of Mounjaro is set at Rs 4,375, while the 2.5 MG vial will be priced at Rs 3,500. This pricing strategy aims to enhance accessibility to this innovative treatment.
Globally, the demand for Lilly's diabetes and weight loss medications is on the rise. The launch of Mounjaro in India represents a significant opportunity, given the country's status as the most populous nation and the increasing prevalence of obesity and diabetes. The company asserts that this drug could serve as a groundbreaking solution for improving metabolic health and facilitating weight loss.
The Seriousness of Diabetes and Obesity in India
Diabetes and obesity are serious problems in India
According to Lilly India, the rise of obesity and type 2 diabetes poses a significant health challenge in the country. With around 101 million individuals suffering from diabetes, obesity is a primary contributor to this condition, highlighting the urgent need for effective solutions.
Mounjaro's Global Usage
The drug is being used a lot in America and Europe
Mounjaro, known chemically as Tirzepatide, is marketed under this name in the UK and Europe for both diabetes management and weight loss. In the United States, it is sold as Zepbound for obesity treatment. Experts predict that the market for obesity medications will expand significantly, with projections estimating sales could reach $150 billion by 2030.
Mechanism of Action
How does this medicine work?
Mounjaro is administered weekly and can cost between ₹14,000 and ₹17,500 monthly, depending on the prescribed dosage. It is the first medication targeting both obesity and type 2 diabetes that activates GIP and GLP-1 hormone receptors. This innovative treatment enhances metabolic health by boosting insulin production, lowering glucagon levels, improving insulin sensitivity, and curbing appetite. It also aids in fat reduction and lipid regulation.
Weight Loss Potential
How much weight can I lose with Monjaro?
A clinical trial published in the New England Journal of Medicine indicates that participants using Mounjaro alongside diet and exercise lost an average of 21.8 kg at the 15 mg dosage and 15.4 kg at the 5 mg dosage over a span of 72 weeks. ref
Rising Demand for GLP-1 Drugs
Increasing demand for GLP-1 drugs
The demand for GLP-1 class medications for diabetes and obesity treatment is surging. This market is now valued in the hundreds of billions. The patent for Semaglutide, a leading drug in this category, will expire in March 2025, prompting several Indian companies to prepare for the launch of generic alternatives.